Andrew Harrow > Goodwin > London, England > Lawyer Profile
Goodwin Offices

Sancroft, 10-15 Newgate Street
London
EC1A 7AZ
England
- Firm Profile
- Go to...
Andrew Harrow

Position
Partner
Career
Andrew Harrow is a partner in the firm’s Life Sciences group. Andrew advises on a wide range of UK and cross-border transactions including joint ventures, mergers and acquisitions, reorganizations, initial public offerings, and fundraisings for listed and private companies internationally as well as general corporate and capital market matters. He has a particular interest in transactions in the life sciences, healthcare, and technology sectors.
Andrew has been noted for his private equity work in The Legal 500 UK, 2016 and recommended in The Legal 500 UK in 2015, 2017 and 2018 in the field of pharmaceuticals and biotechnology; he was also described as “brilliant” with respect to M&A work.
Prior to joining Goodwin in 2018, Andrew was a partner at Dechert LLP.
Education
Legal Practice Course, 1999, Nottingham Law School; Post-Graduate Diploma in Law, 1998, Nottingham Law School; BA, St. John’s College, Oxford
Lawyer Rankings
London > Corporate and commercial > Venture capital
Representing a host of start-ups, emerging growth companies, and late-stage mature corporates, the Goodwin team leverages its ‘strong market knowledge’ to advise on high-value fundraisings and seed rounds. The practice boasts in-depth expertise across healthcare, AI, and environmental matters, often working closely with the firm’s private equity division to support clients in growth equity transactions and complex exits. The team is chaired by David Mardle, an expert in capital markets transactions. Sophie McGrath utilises her ‘vast dealmaking experience’ in private and public financings. Both Andrew Davis and Andrew Harrow primarily focus on joint ventures and growth capital financings. Based in Cambridge, Elizabeth Rhodes and Adam Thatcher are noted for their M&A expertise. Other key figures include Kenny Walker-Durrant, who regularly acts for venture capital investors, as well as Richard Bloomfield and Ella Donegan. Ali Ramadan left to join Cooley (UK) LLP in September 2024.
London > Corporate and commercial > M&A: Lower Mid-Market Deals, £100m-£750m
Goodwin‘s M&A practice has a strong corporate offering and cross-border capabilities which continues to attract new clients, particularly from the life sciences and technology sectors. The team is jointly led by life sciences expert Graham Defries; technology and life sciences authorities David Mardle and Andrew Davis; and real estate specialist James Spence. Defries has extensive experience advising biotech and pharmaceutical companies on private equity and venture capital investments and exits, as well as M&A, corporate financing, and licensing deals – both domestic and cross-border in nature. Davis is praised for his ‘business acumen, attention to detail, and common sense‘, while Spence’s real estate-focused practice encompasses investments in Europe, structured sales and acquisitions, and real estate funds work. Andrew Harrow concentrates on UK and international transactions including joint ventures, M&A, reorganisations, IPOs, and fundraising. Other key names in the team include Adam Thatcher, Lucy Thomas, and Richard Bloomfield.
Lawyer Rankings
- Venture capital London > Corporate and commercial
- M&A: Lower Mid-Market Deals, £100m-£750m London > Corporate and commercial
Top Tier Firm Rankings
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)
- Risk advisory > Regulatory investigations and corporate crime (advice to corporates)
- Corporate and commercial > EU and competition
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)
- Corporate and commercial > Private equity: transactions - mid-market deals (up to £500m)
- Investment fund formation and management > Real estate funds
- Corporate and commercial > Venture capital
Firm Rankings
- Corporate and commercial > M&A: Lower Mid-Market Deals, £100m-£750m
- Investment fund formation and management > Private funds
- Real estate > Commercial property: investment
- TMT (technology, media and telecoms) > Fintech: corporate and commercial
- Industry focus > Hospitality and leisure
- Industry focus > Life sciences and healthcare
- Finance > Acquisition finance
- Corporate and commercial > Corporate tax
- Investment fund formation and management > Fund finance
- Finance > Corporate restructuring & insolvency
- Risk advisory > Data protection, privacy and cybersecurity
- TMT (technology, media and telecoms) > IT and telecoms
- Corporate and commercial > Private equity: transactions – high-value deals (£500m+)
- Real estate > Property finance
- Dispute resolution > Commercial litigation: premium
- Employment > Employers
- Risk advisory > Regulatory investigations and corporate crime (advice to corporates)
- Corporate and commercial > Equity capital markets – small-mid cap
- Corporate and commercial > EU and competition
- Crime, fraud and licensing > Fraud: white-collar crime (advice to individuals)